Literature DB >> 32064623

An emerging role for endothelial barrier support therapy for congenital disorders of glycosylation.

William J Brucker1, Stacy E Croteau2, John R Prensner2, Kate Cullion3, Matthew M Heeney2, Jeffrey Lo4, James B McAlvin3, Katherine Peeler3, Nidhi Shah1, Christina S K Yee4, Gerard T Berry1, Olaf Bodamer1.   

Abstract

Congenital disorders of glycosylation (CDGs) are clinically heterogeneous disorders defined by a decreased ability to modify biomolecules with oligosaccharides. Critical disruptions in protein recognition, interaction, binding, and anchoring lead to broad physiological effects. Patients present with endocrinopathy, immunodeficiency, hepatopathy, coagulopathy, and neurodevelopmental impairment. Patients may experience mortality/morbidity associated with shock physiology that is frequently culture negative and poorly responsive to standard care. Oedema, pleural and pericardial effusions, ascites, proteinuria, and protein-losing enteropathy are observed with an exaggerated inflammatory response. The negative serum protein steady state results from several mechanisms including reduced hepatic synthesis and secretion, increased consumption, and extravasation. Disruption of the glycocalyx, a layer of glycosylated proteins that lines the endothelium preventing thrombosis and extravasation, is a suspected cause of endothelial dysfunction in CDG patients. We performed a retrospective review of CDG patients admitted to our institution with acute illness over the past 2 years. Longitudinal clinical and laboratory data collected during the sick and well states were assessed for biomarkers of inflammation and efficacy of interventions. Six patients representing 4 CDG subtypes and 14 hospitalisations were identified. Acute D-dimer elevation, proteinuria, decreased serum total protein levels, coagulation proteins, and albumin were observed with acute illness. Infusion of fresh frozen plasma, and in some cases protein C concentrate, was associated with clinical and biomarker improvement. This was notable with intra-patient comparison of treated vs untreated courses. Use of endothelial barrier support therapy may reduce endothelial permeability by restoring both regulatory serum protein homeostasis and supporting the glycocalyx and is likely a critical component of care for this population.
© 2020 SSIEM.

Entities:  

Keywords:  congenital disorders of glycosylation; endothelial barrier support therapy; extravasation; fresh frozen plasma; glycocalyx; septic shock

Year:  2020        PMID: 32064623     DOI: 10.1002/jimd.12225

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  7 in total

Review 1.  Nutrition interventions in congenital disorders of glycosylation.

Authors:  Suzanne W Boyer; Christin Johnsen; Eva Morava
Journal:  Trends Mol Med       Date:  2022-05-10       Impact factor: 15.272

2.  Broadly effective metabolic and immune recovery with C5 inhibition in CHAPLE disease.

Authors:  Ahmet Ozen; Nurhan Kasap; Ivan Vujkovic-Cvijin; Richard Apps; Foo Cheung; Elif Karakoc-Aydiner; Bilge Akkelle; Sinan Sari; Engin Tutar; Figen Ozcay; Dilara Kocacik Uygun; Ali Islek; Gamze Akgun; Merve Selcuk; Oya Balci Sezer; Yu Zhang; Gunsel Kutluk; Erdem Topal; Ersin Sayar; Cigdem Celikel; Roderick H J Houwen; Aysen Bingol; Ismail Ogulur; Sevgi Bilgic Eltan; Andrew L Snow; Camille Lake; Giovanna Fantoni; Camille Alba; Brian Sellers; Samuel D Chauvin; Clifton L Dalgard; Olivier Harari; Yan G Ni; Ming-Dauh Wang; Kishor Devalaraja-Narashimha; Poorani Subramanian; Rabia Ergelen; Reha Artan; Sukru Nail Guner; Buket Dalgic; John Tsang; Yasmine Belkaid; Deniz Ertem; Safa Baris; Michael J Lenardo
Journal:  Nat Immunol       Date:  2021-01-04       Impact factor: 25.606

3.  The development of end stage renal disease in two patients with PMM2-CDG.

Authors:  Henna Tiwary; Leah E Hecht; William J Brucker; Gerard T Berry; Nancy M Rodig
Journal:  JIMD Rep       Date:  2022-01-10

4.  A novel homozygous mutation in the human ALG12 gene results in an aberrant profile of oligomannose N-glycans in patient's serum.

Authors:  Jana Ziburová; Marek Nemčovič; Sergej Šesták; Jana Bellová; Zuzana Pakanová; Barbara Siváková; Anna Šalingová; Claudia Šebová; Mária Ostrožlíková; Dimitra-Evanthia Lekka; Jana Brucknerová; Ingrid Brucknerová; Martina Skokňová; Alexandra Mc Cullough; Gabriela Hrčková; Anna Hlavatá; Vladimír Bzdúch; Ján Mucha; Peter Baráth
Journal:  Am J Med Genet A       Date:  2021-09-01       Impact factor: 2.578

5.  Immune dysfunction in MGAT2-CDG: A clinical report and review of the literature.

Authors:  Sheri A Poskanzer; Matthew J Schultz; Coleman T Turgeon; Noemi Vidal-Folch; Kris Liedtke; Devin Oglesbee; Dimitar K Gavrilov; Silvia Tortorelli; Dietrich Matern; Piero Rinaldo; James T Bennett; Jenny M Thies; Irene J Chang; Anita E Beck; Kimiyo Raymond; Eric J Allenspach; Christina Lam
Journal:  Am J Med Genet A       Date:  2020-10-12       Impact factor: 2.802

6.  Liver Involvement in Congenital Disorders of Glycosylation and Deglycosylation.

Authors:  Patryk Lipiński; Anna Bogdańska; Piotr Socha; Anna Tylki-Szymańska
Journal:  Front Pediatr       Date:  2021-07-05       Impact factor: 3.418

Review 7.  P53 in the impaired lungs.

Authors:  Mohammad A Uddin; Nektarios Barabutis
Journal:  DNA Repair (Amst)       Date:  2020-08-19
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.